
FROM THE DESK OF THE GROUP EDITOR-IN-CHIEF



Dr KK Aggarwal President, CMAAO and HCFI Past National President, IMA Group Editor-in-Chief, IJCP Group

CMAAO Coronavirus Facts and Myth Buster: Around the Globe

National Comprehensive Cancer Network (NCCN) – Preliminary Recommendations for COVID-19 Vaccination in Patients with Cancer

Patients receiving hematopoietic cell transplantation or cellular therapy: Coronavirus disease 2019 (COVID-19) vaccination should be done ≥3 months after hematopoietic cell transplantation (allogeneic or autologous) or cellular therapy (e.g., chimeric antigen receptor [CAR] T-cell therapy).

Patients with hematologic malignancies: For patients receiving intensive cytotoxic chemotherapy, vaccination against COVID-19 must be delayed until the absolute neutrophil count has recovered. For patients with marrow failure due to disease or treatment who are

likely to have limited or no recovery, and for those on long-term maintenance therapy, vaccination should be done when the vaccine becomes available.

Patients with solid-tumor malignancies: For patients who are receiving cytotoxic chemotherapy, targeted therapy, checkpoint inhibitor therapy or other immunotherapy, or radiation therapy, vaccination should be done when the vaccine becomes available.

For patients who have to undergo a major surgery, COVID-19 vaccination must be postponed until at least a few days after surgery.

(Excerpts from Medscape)
With input from Dr Monica Vasudev